Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.
about
Nucleic acid sequence-based amplification with oligochromatography for detection of Trypanosoma brucei in clinical samplesStructures of purine nucleosidase from Trypanosoma brucei bound to isozyme-specific trypanocidals and a novel metalorganic inhibitorThree drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in UgandaNECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sicknessSafety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sicknessMelarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the CongoTransport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma brucei2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.Cost-effectiveness of algorithms for confirmation test of human African trypanosomiasis.Cardiac involvement with parasitic infections.Human African trypanosomiasis in South Sudan: how can we prevent a new epidemic?Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study.Treatment perspectives for human African trypanosomiasis.Clinical profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients in Uganda.Kenya Trypanosomiasis Research Institute cryobank for human and animal trypanosome isolates to support research: opportunities and challenges.Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sicknessHuman African trypanosomiasis of the CNS: current issues and challengesTowards Point-of-Care Diagnostic and Staging Tools for Human African Trypanosomiaisis.Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sicknessTrypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.Effective measures for controlling trypanosomiasis.Treatment options for second-stage gambiense human African trypanosomiasis.Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.HIV-1/parasite co-infection and the emergence of new parasite strains.Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis.Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.Functional analysis of drug resistance-associated mutations in the Trypanosoma brucei adenosine transporter 1 (TbAT1) and the proposal of a structural model for the protein.Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.Quantifying the level of under-detection of Trypanosoma brucei rhodesiense sleeping sickness cases.The phenomenon of treatment failures in Human African Trypanosomiasis.Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment.Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.The story of CGP 40 215: studies on its efficacy and pharmacokinetics in African green monkey infected with Trypanosoma brucei rhodesiense.Susceptibility Testing of Medically Important Parasites.Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo.Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatBDrug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania.Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis.Future treatment options for human African trypanosomiasis.
P2860
Q24645104-1EF41098-625C-4B61-A92B-07CE40891635Q27685304-7D929721-35A0-475D-B93B-91697CB86713Q28469079-4F1AF0D4-3627-406D-86C3-C5EA51AB9D6AQ28474074-5AA5A2DF-30C1-4422-A103-B8C9D28A6775Q28483501-45333A66-E9C9-4EDF-AAB4-68B02B5FB556Q28543489-A728202E-EC02-4DF8-A23B-6010421DB0BCQ28652499-1BDDF240-E856-49F4-8958-486D7AF80452Q33294205-E1FACE34-7F87-4C5C-8215-BCE66713713EQ33776699-CBEE761E-C82F-46A6-BCEF-69CD848AEC8FQ33825602-4E56523B-A37E-4232-8801-00C5ED1E3263Q34293008-AB8BE74D-7EA1-4F81-B4C8-433A087CDB14Q34589130-AA3902AD-A3A1-4FB1-A3AA-2FDB391DA40CQ35095248-83ED39A9-BBA2-4827-ACA0-6E41C9E480B5Q35126176-EA9E25E7-57DC-4C22-92B4-446CA465FEDDQ35172655-0015027A-27A1-41F9-830A-6B1757C0F065Q35598430-599A1A0F-3F70-463E-9125-1A28F6BA5224Q35668843-50356F8E-57EF-40BC-9644-8E5149CF1BB9Q35876057-92B01BE6-F241-4CEE-8BD1-FF3FE531DF1EQ35946968-85A82A67-A104-4D59-9C42-7A117745EAC7Q36009318-ED660F80-D04A-41AC-A4AF-694E62105DE9Q36326229-D3FD0B0D-62A6-4607-A1C9-2D4516EBAC9CQ36551049-EBDA728E-A26B-4E11-9C76-ADDEFDD0377FQ36740553-B1F7E915-33AB-45FF-B745-0E20DEA1F86CQ37120966-6AA24DFE-E8D2-4DFE-9256-5A38100A35CEQ37449679-4873A2C3-7CC9-4E6D-A520-7177C90F79BAQ37981773-09146EA6-B2E1-4173-B89D-DF6E790C8E12Q38495661-86B8AF53-AE14-47A1-8410-108613535CB6Q38875419-B3395FDC-A2BD-424E-96B5-300725BDDD48Q38880548-E2B10D6B-CB4E-463C-950B-D3271D4FD373Q38884830-CEA4A7BA-E8F8-47AD-AB96-0CD3E751A9C1Q38885263-3BA785B2-A52A-44D3-917F-92DA05937F80Q38885267-6C1384DB-D4EE-422F-87E3-E4521AA8D13EQ38923941-68A011E3-21FB-4C7A-AFAF-E71AAEAB62C4Q39020376-5064C60A-7DE0-42C3-8BAE-D6F5ED6060B7Q39223286-801FB1A1-0FBE-47F4-A87E-56A2BE57114AQ39401311-DDE9F533-B2D0-4E75-A7D2-5F47B1608DC9Q39412077-D5D980DA-238C-40A4-87E9-E06CB2D7FCECQ43947251-35130707-EF02-4D66-9873-0A63B37077A1Q44133382-F398416D-D96E-4B11-8A34-62069CCDEADDQ48373153-E62A5B84-F3CD-4BD6-B1CF-8E270B56DBDD
P2860
Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Risk factors for treatment fai ...... nse trypanosomiasis in Uganda.
@en
type
label
Risk factors for treatment fai ...... nse trypanosomiasis in Uganda.
@en
prefLabel
Risk factors for treatment fai ...... nse trypanosomiasis in Uganda.
@en
P2093
P921
P1476
Risk factors for treatment fai ...... nse trypanosomiasis in Uganda.
@en
P2093
P304
P356
10.1016/S0035-9203(99)90151-7
P577
1999-07-01T00:00:00Z